EAVI2020 EAVI2020 on Twitter EAVI2020 on Facebook EAVI2020 on LinkedIn

Search

for a vaccine

Publications

Publications

The EAVI2020 project has contributed to many scientific publications. Below is a list of these publications and their journal links. All are freely accessible and acknowledge EAVI2020’s funding body, the European Commission:

      • Vieillard, V., Combadière, B., Tubiana, R., Launay, O., Pialoux, G., Cotte, L.,  Girard, PM., Simon, A., Dudoit, Y., Reynes, J., Rockstroh, J., Garcia, F., Gatell, J., Devidas, A., Yazdanpanah, Y., Weiss, L., Fätkenheuer, G., Autran, B., Joyeux, D., Gharakhanian, S., Debré, P., Katlama, C. (2019). HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomized phase 2 trialnpj Vaccines Volume 4(25). DOI: 10.1038/s41541-019-0117-5
      • Brouwer, P.J.M., Antanasijevic, A., Berndsen, Z., Yasmeen, A., Fiala, B., Bijl, T.P.L., Bontjer, I., Bale, J.B., Sheffler, W., Allen, J.D., Schorcht, A., Burger, J.A., Camacho, M., Ellis, D., Cottrell, C.A., Behrens, AJ., Catalano, M., del Moral-Sánchez, I., Ketas, T.J., LaBranche, C., van Gils, M.J., Sliepen, K., Stewart, L.J., Crispin, M., Montefiori, D.C., Baker, D., Moore, J.P., Klasse, P.J., Ward, A.B., King, N.P., Sanders, R.W. (2019). Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticleNature Communications. Volume 10 (4272). September 19. DOI: 10.1038/s41467-019-12080-1
      • Sliepen K, Han B.W., Bontjer I, Mooij P, Garces F, Behrens A, Rantalainen K, Kumar S, Sarkar A, Brouwer P.J.M., Hua Y, Tolazzi M, Schermer E, Torres J.L., Ozorowski G, van der Woude P, de la Peña A.T., van Breemen M.J., Camacho-Sánchez J.M., Burger J.A., Medina-Ramírez. M, González. N, Alcami.J, LaBranche.C, Scarlatti G, van Gils M.J., Crispin M, Montefiori D.C., Ward A.B., Koopman G, Moore J.P., Shattock R.J., Bogers W.M., Wilson I.A., and Sanders. R.W. (2019). Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications DOI: 10.1038/s41467-019-10262-5
      • van Gils M.J., van den Kerkhof T.L., Ozorowski G, Cottrell C.A., Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye S.W., Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang C.H., Landais E, Nie X, Pritchard L.K., Crispin M, Kelsoe G, Wilson I.A., Schuitemaker H, Klasse P.J., Moore J.P., Burton D.R., Ward A.B., Sanders R.W. (2016). An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2(16199). DOI: 10.1038/nmicrobiol.2016.199

The EAVI2020 project has contributed to many scientific publications. Below is a list of these publications and their journal links. All are freely accessible and acknowledge EAVI2020’s funding body, the European Commission:

      • Vieillard, V., Combadière, B., Tubiana, R., Launay, O., Pialoux, G., Cotte, L.,  Girard, PM., Simon, A., Dudoit, Y., Reynes, J., Rockstroh, J., Garcia, F., Gatell, J., Devidas, A., Yazdanpanah, Y., Weiss, L., Fätkenheuer, G., Autran, B., Joyeux, D., Gharakhanian, S., Debré, P., Katlama, C. (2019). HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomized phase 2 trialnpj Vaccines Volume 4(25). DOI: 10.1038/s41541-019-0117-5
      • Brouwer, P.J.M., Antanasijevic, A., Berndsen, Z., Yasmeen, A., Fiala, B., Bijl, T.P.L., Bontjer, I., Bale, J.B., Sheffler, W., Allen, J.D., Schorcht, A., Burger, J.A., Camacho, M., Ellis, D., Cottrell, C.A., Behrens, AJ., Catalano, M., del Moral-Sánchez, I., Ketas, T.J., LaBranche, C., van Gils, M.J., Sliepen, K., Stewart, L.J., Crispin, M., Montefiori, D.C., Baker, D., Moore, J.P., Klasse, P.J., Ward, A.B., King, N.P., Sanders, R.W. (2019). Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticleNature Communications. Volume 10 (4272). September 19. DOI: 10.1038/s41467-019-12080-1
      • Sliepen K, Han B.W., Bontjer I, Mooij P, Garces F, Behrens A, Rantalainen K, Kumar S, Sarkar A, Brouwer P.J.M., Hua Y, Tolazzi M, Schermer E, Torres J.L., Ozorowski G, van der Woude P, de la Peña A.T., van Breemen M.J., Camacho-Sánchez J.M., Burger J.A., Medina-Ramírez. M, González. N, Alcami.J, LaBranche.C, Scarlatti G, van Gils M.J., Crispin M, Montefiori D.C., Ward A.B., Koopman G, Moore J.P., Shattock R.J., Bogers W.M., Wilson I.A., and Sanders. R.W. (2019). Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications DOI: 10.1038/s41467-019-10262-5
      • van Gils M.J., van den Kerkhof T.L., Ozorowski G, Cottrell C.A., Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye S.W., Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang C.H., Landais E, Nie X, Pritchard L.K., Crispin M, Kelsoe G, Wilson I.A., Schuitemaker H, Klasse P.J., Moore J.P., Burton D.R., Ward A.B., Sanders R.W. (2016). An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2(16199). DOI: 10.1038/nmicrobiol.2016.199